Laurus Labs gets one observation from USFDA for pre-approval inspection

31 Oct 2022 , 10:23 AM

Laurus Labs Limited has informed that US Food and Drug Administration (USFDA) has completed a PreApproval Inspection (PAI) at Company’s manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh.

The inspection was conducted from October 24, 2022 to October 28, 2022, the company said.

The company has been issued a Form 483 with one observation. The observation is procedural in nature.

Further, the Company informed that it will address the observation within stipulated timelines.

At around 10:23 AM, Laurus Labs Ltd is currently trading at Rs449.95 per share up by Rs5.3 or 1.19% from its previous closing of Rs444.65 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]